Aline Cuenod, MSc
University of Basel
Tel: +41 265 23 23
Since 08/2017 PhD Student at the Department of Biomedicine (DBM), University of Basel, Basel, Switzerland and the Clinical Microbiology Unit of the University Hospital of Basel (USB), Basel, Switzerland
Education and previous posts
05/2017 – 06/2017 Internship Identification of Microorganisms using MALDI-TOF MS at Mabritec AG, Riehen, Switzerland
09/2015 – 02/2017 Master of Science in Infection Biology, Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland. Masterthesis: “A ribosomal marker based approach for identification of five Klebsiella species by MALDI-TOF MS: unexpected high prevalence of Klebsiella michiganensis and Klebsiella variicola in clinical isolates from Switzerland”, supervised by PD Dr. Claudia Daubenberger
05/2015 – 06/2015 Internship Clinical, Genetic Diagnostic, Ege University, Izmir, Turkey
07/2014 – 12/2014 Inernship Clinical, Microorganism Diagnostic, Laborgemeinschaft 1 / Medibact AG, Zürich / Basel, Switzerland
09/2011 – 06/2014 Bachelor of Science in molecular Biology, University of Basel, Basel, Switzerland
Enterobacteriacea are part of the human gut flora and occasionally cause infections, for instance of the urinary or the respiratory tract. In hospital settings however, species of this family are a major threat as they often harbour antibiotic resistances and are a frequent cause of nosocomial outbreaks. Interestingly, the description of hypervirulent strains which cause heavy disease in healthy hosts increased during the past years. What factors enable a bacterial strain to become dangerous to human life whereas its close relatives are harmless?
For my PhD project I compare clinical Enterobacteriacea isolates which are associated to different severity of infection using Next Generation Sequencing (NGS) and Matrix Assisted Laser Desorption Ionization-Time of Fight Mass Spectrometry (MALDI-TOF MS). The aim is to identify virulence markers which can be detected in daily, microbiological routine diagnostics. Recognising
hypervirulent strains as early can improve the medical treatment and help to prevent nosocomial outbreaks (Holt et al., 2015).